Elizabeth McKenna· @ElizSMcKenna · X·· 2026-04-19Score60
Body
Find out more on overcoming BTK inhibitor resistance in CLL by #AACR26 speaker Jennifer Woyach in
@CD_AACR
in the phase I of nemtabrutinib, an orally bioavailable, reversible, ATP-competitive BTK inhibitor designed to inhibit both WT and C481S-mutated BTK
https://
doi.org/10.1158/2159-8
290.CD-23-0670
…
Heat 3 · 3 likes · 0 replies · 0 reposts
Conference abstracts
982matched by 药名 nemtabrutinib
Pharmacophore profiling highlights diverging binding modes of nemtabrutinib and ibrutinib across tyrosine kinasesCharly Empereur-mot, Giulio Sartori, Luca Pesce, Filippo Spriano, Chiara Tarantelli, Luciano Cascione, Alberto J. Arribas, Luca Aresu, Davide Rossi, Giovanna L.M. Damia, Massimo Broggini, Daniela Polino, Francesco Bertoni
Read the abstract →Source: Elizabeth McKenna · x.com